Ligand Pharmaceuticals - Biopharma's Technology and Capital …
Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the …
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
2025年2月27日 · Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We achieved …
Ligand Pharmaceuticals Incorporated - Investor Relations
2025年2月27日 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of …
About Us - Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs …
Ligand Leads $75 Million Royalty Financing in Castle Creek …
2025年2月25日 · Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s NITRICIL™ …
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 …
2024年12月10日 · At today’s event, Ligand’s senior management team will highlight: Ligand’s transformation over the past two years into a profitable, diversified, and infrastructure light …
Team - Ligand Pharmaceuticals
Todd Davis is Chief Executive Officer of Ligand and has served on the company’s Board of Directors since 2007. He has more than 30 years of operational and investment experience …
Ligand to Acquire APEIRON Biologics AG for $100 Million
2024年7月8日 · QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the beginning of 2023. Transaction will be immediately accretive to Ligand EPS by an …
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE ...
2024年6月18日 · Ligand will now collect commercial royalties on six products developed with the Pfenex Expression Technology, including Merck’s CAPVAXIVE and VAXNEUVANCE ®, Jazz …
Ligand Reports Third Quarter 2024 Financial Results and Raises …
Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. …